Jade Biosciences, Inc. · NASDAQ:JBIO
Jade Biosciences — ERA 2025 Conference Call
19 slides from Jade Biosciences's conference presentation, Jun 9, 2025
Slide 1: ERA 2025 Conference Call
ERA 2025 Conference Call June 9, 2025 NASDAQ: JBIO
Slide 2: Disclaimers
Disclaimers Forward Looking Statements Certain statements in this presentation, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities
Slide 3: Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases
Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases Current funding expected to support operations through 2027, well beyond biomarker-rich JADE101 healthy volunteer data Planned Potential MOA Program Candidate Discovery IND-enabling Interim HV Data Clinical FIH
Slide 4: Jade is developing a potentially best-in-class anti-APRIL mAb
Jade is developing a potentially best-in-class anti-APRIL mAb Estimated Current treatments do not adequately Anti-APRIL Mechanism has potential to be disease $10B+ address the need for long-term disease- modifying therapy in class poised to be frontline treatment modifying, reducing pathogenic IgA a
Slide 5: Proposed updates to KDIGO guidelines support the frontline therapeutic potential of the anti-APRIL class in IgAN
Proposed updates to KDIGO guidelines support the frontline therapeutic potential of the anti-APRIL class in IgAN IgAN patients at risk Expanding Patient Population of progressive kidney function loss • Kidney biopsy recommended in all adults with proteinuria ≥0.5 g/d where IgAN is a possible diagnos
Slide 6: Potentially best-in-class profile of JADE101
Potentially best-in-class profile of JADE101 Femtomolar APRIL Affinity + Half Life Extension Potentially best-in-class Infrequent Q8W+ dosing Avoids unnecessary efficacy immunosuppression APRIL inhibitors demonstrate Minimizes burden in a typically Selectively targeting APRIL provides greater protei
Slide 7: Potentially best-in-class properties of JADE101
Potentially best-in-class properties of JADE101 Ultra-high (fM) APRIL binding Novel IP for composition affinity of matter into mid-2040s • Binds APRIL to neutralize activity • Greater APRIL binding affinity than sibeprenlimab, zigakibart, povetacicept and atacicept De novo antibody discovery Half-li
Slide 8: Presentation at the 62nd European Renal Association Congress
JADE101 Presentation at the 62nd European Renal Association Congress 8
Slide 9: JADE101 binds to APRIL with ultra-high affinity
JADE101 binds to APRIL with ultra-high affinity SPR binding of JADE101 or sibeprenlimab* to recombinant human APRIL JADE101 binds a novel epitope with important functional implications *Sibeprenlimab generated from publicly available sequence. YTE-Sibe was engineered on the IgG1 framework. PK parame
Slide 10: JADE101 blocks binding of APRIL to BCMA and TACI, inhibiting APRIL-mediated signaling
JADE101 blocks binding of APRIL to BCMA and TACI, inhibiting APRIL-mediated signaling BCMA TACI Binding Signaling JADE101 potently and completely blocks the binding of APRIL to its two receptors, BCMA and TACI, and fully prevents APRIL mediated signaling through both BCMA and TACI, in vitro. BCMA (A
Slide 11: JADE101 inhibits human plasma cell proliferation and IgA production in vitro
JADE101 inhibits human plasma cell proliferation and IgA production in vitro Plasma Cell Proliferation IgA Production This effect to block APRIL mediated plasma cell proliferation and IgA production, is a key mechanism by which anti-APRIL therapies deliver disease-modifying impact in IgAN patients.
Slide 12: JADE101 exhibits a highly differentiated NHP PK/PD profile (Single IV Dose)
JADE101 exhibits a highly differentiated Single IV Dose NHP PK/PD profile >3X increased half-life compared to sibeprenlimab in NHPs Accompanied by deep and prolonged IgA reduction JADE101 has the potential to extend dosing interval through low clearance via half-life extension, target-mediated drug
Slide 13: JADE101 exhibits a highly differentiated NHP PK/PD profile (Single SC Dose)
JADE101 exhibits a highly differentiated Single SC Dose NHP PK/PD profile High bioavailability with long slow linear clearance phase Accompanied by deep and prolonged IgA reduction JADE101 has the potential to extend dosing interval through low clearance via half-life extension, target-mediated drug
Slide 14: JADE101 avoids high molecular weight complex formation
JADE101 avoids high molecular weight complex formation High MW complex formation can occur with mAbs binding trimeric proteins, such as APRIL. Avoiding high MW complexes potentially mitigates risks of immunogenicity and TMDD. MW - molecular weight, TMDD - target mediated drug disposition, mAbs – mon
Slide 15: ERA2025: JADE101 key takeaways
ERA2025: JADE101 key takeaways • JADE101 binds a novel APRIL epitope with ultra-high affinity. • JADE101 potently inhibits APRIL-mediated signaling through BCMA and TACI reducing plasma cell proliferation and IgA production in vitro. • JADE101 exhibits an extended PK half-life, significantly attenua
Slide 16: Anticipated 1H26 HV data potentially positions JADE101 for accelerated development
Anticipated 1H26 HV data potentially positions PK, APRIL and IgA HV will define the dose and schedule designed to fully suppress APRIL JADE101 for accelerated development throughout the dosing interval in IgAN patients. MOA Program IND Enabling Phase 1 Initiation Interim Healthy Volunteer Data Poten
Slide 17: Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases
Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases Current funding expected to support operations through 2027, well beyond biomarker-rich JADE101 healthy volunteer data Planned Potential MOA Program Candidate Discovery IND-enabling Interim HV Data Clinical FIH
Slide 18: Jade Biosciences ERA 2025: Q&A
Jade Biosciences ERA 2025: Q&A Tom Frohlich Andrew King, BVMS, Ph.D. Chief Executive Officer Chief Scientific Officer & Head of R&D 18
Slide 19: Thank you
Thank you www.JadeBiosciences.com | info@jadebiosciences.com NASDAQ: JBIO